Led by Dr. Angus Nairn and Dr. Anita Huttner, the Neuropathology Core provides post-mortem diagnoses and biomarker analyses for patients and control subjects enrolled in the Clinical Core as well as for other well documented AD cases and controls.
The Yale Neuropathology Core conducts postmortem examinations on Yale-ADRC patients and for other well documented AD cases and controls; and maintains a bank of unfixed frozen and fixed tissue from the ADRC control and patients with AD or other dementing neurodegenerative conditions.
The Neuropathology Core provides staff, technical resources, laboratory facilities and expertise in quantitative targeted mass spectrometric assays for the analysis of human AD brain samples and biofluids. This will include analysis of unfractionated and fractionated brain tissue, and CSF using targeted mass spectrometry methods. It also will establish procedures for generation of Induced Pluripotent Stem Cells (iPSCs) from human AD patients.
The Neuropathology Core closely interacts with the other Cores of the Yale ADRC and provides tissue, methodologies and advice to Projects and Pilot Projects users in the ADRC and Yale researchers with an interest in AD, neurodegenerative disease and aging, as well as with other ADRCs.